
Pharvaris B.V. (PHVS) Stock Forecast & Price Target
Pharvaris B.V. (PHVS) Analyst Ratings
Bulls say
Pharvaris NV is a late-stage biopharmaceutical company focused on developing deucrictibant, an oral bradykinin B2 receptor antagonist, for the treatment and prevention of hereditary angioedema (HAE) attacks. The company is actively enrolling participants in a pivotal Phase 3 study, with the potential for further upside related to an ultra-orphan indication, enhancing the attractiveness of its asset given the estimated prevalence within the target population. The unique dual modes of treatment offered by deucrictibant create a distinctive position for Pharvaris in the HAE landscape, suggesting a strong scarcity value for its product.
Bears say
Pharvaris NV faces significant financial challenges that may hinder its ability to advance its drug development pipeline, primarily due to potential difficulties in raising adequate funding. Additionally, while the company has identified unmet needs in related angioedema conditions, there remains considerable uncertainty regarding the market viability of its lead product, deucrictibant. This combination of funding concerns and market uncertainties contributes to a negative outlook on Pharvaris's stock.
This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.
Pharvaris B.V. (PHVS) Analyst Forecast & Price Prediction
Start investing in Pharvaris B.V. (PHVS)
Order type
Buy in
Order amount
Est. shares
0 shares